Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals (HIK)

Buy
Sell
Company name:Hikma Pharmaceuticals Plc
EPIC:HIKTrading Currency:GBX
Market Sector:FS10ISIN:GB00B0LCW083
Market Segment:SET1Share Type:DE
WWW Address:http://www.hikma.com/Description:ORD SHS 10P
Industry Sector:PHARMACEUTICALS & BIOTECHNOLOGY
 Price Price Change [%] Bid Offer Open High Low Volume
 2,644.00 images.advfn.com/imagesnew/2/gb/up 24.0 [0.92] 2,640.00 2,642.00 2,629.00 2,650.00 2,621.00 179,486
 Market Cap. [m] Shares In Issue [m] Beta EPS DPS PE Ratio Yield 52-Wks-Range
 6,120.14 231.47 -0.87 132.57 36.57 19.94 1.38 2,766.00 - 2,125.00

Hikma Pharmaceuticals Key Figures

(at previous day's close)
Market Cap.6,120.14m
Shares In Issue231.47m
Prev. Close2,620.00
PE Ratio19.94 
Dividend Yield1.38%
EPS - basic132.57p
Dividend PS36.57p
Dividend Cover- 
Cash Flow PS146.62p
Return On Equity (ROE)20.19%
Operating Margin23.84%
PEG Factor-2.20 
EPS Growth Rate-9.06%
Dividends PS Growth Rate13.64%
Net Debt1,214.16m
Gross Gearing48.05%
Quick Assets1,013.75m
Net Working Capital815.53m
Intangibles / Fixed Assets46.94%
Turnover PS739.72p
Pre-Tax Profit PS176.32p
Retained Profit PS101.75p
Cash PS103.33p
Net Cash PS-221.51p
Net Tangible Asset Value PS *379.18p
Net Asset Value PS678.74p
Spread2.00 (0.08%) 

Hikma Pharmaceuticals Balance Sheet

L^HIK:Liabilities+EQL^HIK:Assets

Share Price Performance

Sample Period HighLow
1 week2,667.002,564.00
4 weeks2,667.002,380.00
12 weeks2,667.002,277.00
1 year2,766.002,125.00

Share Price Chart (5 years)

Hikma Pharmaceuticals Historic Returns

Period OpenChange%Open Avg.Avg. Daily Vol [m]Total Vol [m]VWAP
1 week2,595.0049.001.892,564.000.322,623.39
4 weeks2,402.00242.0010.072,380.000.332,560.16
12 weeks2,391.00253.0010.582,277.000.382,457.96
26 weeks2,490.00154.006.182,158.000.452,380.79
1 year2,188.00456.0020.842,125.000.532,447.31
3 years1,620.001,024.0063.211,491.500.682,098.19
5 years2,588.0056.002.16814.200.711,845.04

Hikma Pharmaceuticals Key Management Ratios

Hikma Pharmaceuticals Investment Ratios

(Market value analysis) at previous day's close
PQ Ratio17.90 
PE Ratio19.94 
Tobin's Q Ratio 1.52 
Tobin's Q Ratio (excl. intangibles)1.96 
Dividend Yield1.38%
Market-to-Book Ratio3.92 
Price-to-Pre-Tax Profit PS15.00 
Price-to-Retained Profit PS25.99 
Price-to-Cash Flow PS18.03 
Price-to-Sales PS3.57 
Price-to-Net Tangible Asset Value PS6.90 
Price-to-Cash PS25.59 
Net Working Capital PS352.32 
Price Pct to Working Capital PS7.50%
Earnings Yield5.01%
Average PE16.60 
Years in average4 
PE to PE average120.17%

Hikma Pharmaceuticals Financial Ratios

(Leverage Ratios)
Debt Ratio30.87%
Debt-to-Equity Ratio0.45 
Debt-to-Equity Ratio (excl. Intgbl)0.79 
Debt-to-Equity Market Value0.11 
Net Gearing40.15%
Net Gearing (excl. Intangibles)51.87%
Gross Gearing48.05%
Gross Gearing (excl. Intangibles)62.09%
Gearing Under 1 Year24.86%
Gearing Under 1 Year (excl. Intgbl)32.12%
Assets/Equity1.93 
Cash/Equity15.22 
(Liquidity Ratios)
Net Working Capital to Total Assets26.96%
Current Ratio2.08 
Quick Ratio (Acid Test)1.35 
Liquidity Ratio0.32 
Cash & Equiv/Current Assets15.26%
(Solvency Ratios)
Enterprise Value6,591.91m
CFO/Sales0.20 
CFO/Attributable Profit1.08 
CFO/Assets0.11 
CFO/Debt0.23 
Total Debt/Equity Market Value0.24 
Total Debt/Sales0.85 
Total Debt/Pre-Tax Profit3.56 
Total Debt1,453.33m
Total Debt/Net Current Assets1.78%
(Dodds - Graham Ratios)
3 yr Compound Earnings Growth15.99%
5 yr Compound Earnings Growth22.39%
10 yr Compound Earnings Growth16.03%
Earn drops > 5% in 10yrs6 
Beta (60-Mnth)Beta (36-Mnth)
-0.8673-0.4631

Hikma Pharmaceuticals Operating Ratios

(Profitability Ratios)
Return On Capital Employed (ROCE)17.96%
Return On Assets (ROA)7.82%
Net Profit Margin18.41%
Assets Turnover0.42 
Return On Equity (ROE)20.19%
Return On Investment (ROI)11.33%
Dividend Payout Ratio27.38%
Plowback Ratio72.62%
Growth from Plowback Ratio10.77%
Net Income Of Revenues13.75%
(Asset Utilisation Multiples)
Shareholders Equity Turnover0.81 
Fixed Assets Turnover0.89 
Current Assets Turnover0.81 
Net Working Capital Turnover 
Inventory Turnover2.58 
(Other Operating Ratios)
Total Assets-to-Sales2.36 
Debtors-to-Sales59.98%
Debt Collection Period218.93Days

Hikma Pharmaceuticals Dividends

Announcement DateTypeCurr.Dividend AmountPeriod StartPeriod EndEx DateRecord DatePayment DateTotal Dividend Amount
25 Feb 2021FinalUSX34.0031/12/201931/12/202018/03/202119/03/202126/04/202150.00
07 Aug 2020InterimUSX16.0031/12/201931/12/202020/08/202021/08/202021/09/2020-
27 Feb 2020FinalUSX30.0031/12/201831/12/201919/03/202020/03/202007/05/202044.00
09 Aug 2019InterimUSX14.0031/12/201831/12/201922/08/201923/08/201923/09/2019-
13 Mar 2019FinalUSX26.0031/12/201731/12/201804/04/201905/04/201922/05/201938.00
15 Aug 2018InterimUSX12.0031/12/201731/12/201823/08/201824/08/201821/09/2018-
14 Mar 2018FinalUSX23.0031/12/201631/12/201705/04/201806/04/201824/05/201834.00
17 Aug 2017InterimUSX11.0031/12/201631/12/201724/08/201725/08/201722/09/2017-
15 Mar 2017FinalUSX22.0031/12/201531/12/201606/04/201707/04/201725/05/201733.00
26 Aug 2016InterimUSX11.0031/12/201531/12/201601/09/201602/09/201630/09/2016-
16 Mar 2016FinalUSX21.0031/12/201431/12/201507/04/201608/04/201619/05/201632.00
19 Aug 2015InterimUSX11.0031/12/201431/12/201527/08/201528/08/201525/09/2015-
11 Mar 2015FinalUSX9.9031/12/201331/12/201416/04/201517/04/201521/05/201516.90
11 Mar 2015SpecialUSX4.0031/12/201331/12/201416/04/201517/04/201521/05/2015-
20 Aug 2014SpecialUSX4.0031/12/201331/12/201427/08/201429/08/201426/10/2014-
20 Aug 2014InterimUSX7.0031/12/201331/12/201427/08/201429/08/201426/10/2014-
12 Mar 2014FinalUSX7.8031/12/201231/12/201323/04/201425/04/201422/05/201412.30
12 Mar 2014SpecialUSX2.4031/12/201231/12/201323/04/201425/04/201422/05/2014-
21 Aug 2013InterimUSX4.5031/12/201231/12/201304/09/201306/09/201307/10/2013-
21 Aug 2013SpecialUSX1.9031/12/201231/12/201304/09/201306/09/201307/10/2013-
13 Mar 2013FinalUSX10.0031/12/201131/12/201217/04/201319/04/201323/05/201316.00
16 Aug 2012InterimUSX6.0031/12/201131/12/201229/08/201231/08/201208/10/2012-
14 Mar 2012FinalUSX7.5031/12/201031/12/201118/04/201220/04/201224/05/201213.00
25 Aug 2011InterimUSX5.5031/12/201031/12/201107/09/201109/09/201113/10/2011-
16 Mar 2011FinalUSX7.5031/12/200931/12/201013/04/201115/04/201126/05/201113.00
26 Aug 2010InterimUSX5.5031/12/200931/12/201008/09/201010/09/201014/10/2010-
17 Mar 2010FinalUSX6.5031/12/200831/12/200914/04/201016/04/201027/05/201011.00
17 Mar 2009FinalUSX4.0031/12/200731/12/200829/04/200901/05/200902/06/20097.50
27 Aug 2009InterimUSX4.5030/12/200730/06/200816/09/200918/09/200916/10/2009-
28 Aug 2008InterimUSX3.5030/12/200730/06/200817/09/200819/09/200817/10/2008-
18 Mar 2008FinalUSX4.0001/07/200731/12/200730/04/200802/05/200802/06/20087.50
05 Sep 2007InterimUSX3.5030/12/200630/06/200726/09/200728/09/200726/10/2007-
20 Mar 2007FinalUSX2.1031/12/200531/12/200616/05/200718/05/200718/06/20073.70
13 Sep 2006InterimUSX1.6030/12/200530/06/200627/09/200629/09/200627/10/2006-
25 May 2006FinalUSX0.4731/12/200431/12/200526/04/200628/04/200630/05/20060.47

Hikma Pharmaceuticals Fundamentals

 31 Dec 2017 (USD)31 Dec 2018 (USD)31 Dec 2019 (USD)31 Dec 2020 (USD)
turnover1,936.00100.00%2,070.00100.00%2,203.00100.00%2,341.00100.00%m
pre tax profit-738.00-38.12%293.0014.15%491.0022.29%558.0023.84%m
attributable profit-843.00-43.54%282.0013.62%486.0022.06%431.0018.41%m
retained profit-922.00-47.62%198.009.57%389.0017.66%322.0013.75%m
eps - basic-351.30 117.00 200.80 182.60 
eps - diluted-349.80 116.50 200.00 181.10 
dividends per share34.00 38.00 44.00 50.00 

Hikma Pharmaceuticals Balance Sheet

 31 Dec 2017 (USD)31 Dec 2018 (USD)31 Dec 2019 (USD)31 Dec 2020 (USD)
L^HIK:Liabilities+EQL^HIK:AssetsL^HIK:Liabilities+EQL^HIK:AssetsL^HIK:Liabilities+EQL^HIK:AssetsL^HIK:Liabilities+EQL^HIK:Assets
 31 Dec 2017 (USD)31 Dec 2018 (USD)31 Dec 2019 (USD)31 Dec 2020 (USD)
ASSETS
fixed assets fixed assets828.0024.44%870.0024.88%912.0023.21%1,009.0024.40%m
intangibles intangibles785.0023.17%766.0021.90%884.0022.49%935.0022.61%m
fixed investments fixed investments66.001.95%68.001.94%43.001.09%48.001.16%m
current assets - other current assets - other95.002.80%59.001.69%39.000.99%46.001.11%m
stocks stocks488.0014.40%528.0015.10%568.0014.45%757.0018.31%m
debtors debtors895.0026.42%930.0026.59%1,041.0026.49%1,013.0024.50%m
cash & securities cash & securities231.006.82%276.007.89%443.0011.27%327.007.91%m
TOTAL3,388.00100%3,497.00100%3,930.00100%4,135.00100%m
LIABILITIES
creditors - short creditors - short797.0023.52%893.0025.54%1,471.0037.43%1,028.0024.86%m
creditors - long creditors - long1,063.0031.38%907.0025.94%330.008.40%959.0023.19%m
creditors - other creditors - other--%--%--%--%m
subordinated loans subordinated loans--%--%--%--%m
insurance funds insurance funds--%--%--%--%m
TOTAL1,860.0054.90%1,800.0051.47%1,801.0045.83%1,987.0048.05%m
EQUITY
ord cap, reserves ord cap, reserves1,514.0044.69%1,685.0048.18%2,117.0053.87%2,135.0051.63%m
prefs, minorities prefs, minorities14.000.41%12.000.34%12.000.31%13.000.31%m
TOTAL1,528.0045.10%1,697.0048.53%2,129.0054.17%2,148.0051.95%m
OTHER
NAV Basic- - - - 
NAV Diluted- - - - 

Hikma Pharmaceuticals Cash Flow Statement

31 Dec 2017 (USD)31 Dec 2018 (USD)31 Dec 2019 (USD)31 Dec 2020 (USD)
Operating CF443.00430.00472.00464.00m
Pre-Financing CF292.00334.00321.00181.00m
Retained CF72.0056.00166.00-117.00m

Hikma Pharmaceuticals Brokers

NameActivityTypeMnemonicCode
Deutsche Bank AG London BranchMarket Maker(MME)Broker/DealerDEUTDEUTGB2L
Evolution Securities LimitedMarket Maker(MME)Broker/DealerEVOEVBGGB21MMT
Jefferies International LtdMarket Maker(MME)Broker/DealerJEFFJEFFGB2X
J.P. Morgan Securities LtdMarket Maker(MME)Broker/DealerJPMSJPMSGB2L
Citigrp Global Mkt UK EquitiesMarket Maker(MME)Broker/DealerCITISBUKGB21
Merrill Lynch InternationalMarket Maker(MME)Broker/DealerMLSBSNCSGB2LBIC
UBS AGMarket Maker(MME)Broker/DealerUBS.UBSWGB2LEQU
Winterflood Securities LtdMarket Maker(MME)Broker/DealerWINSWNTSGB2LBIC
ADVFN Advertorial
Your Recent History
LSE
HIK
Hikma Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210725 22:58:45